Shen Jie, Ambrosone Christine B, DiCioccio Richard A, Odunsi Kunle, Lele Shashikant B, Zhao Hua
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Carcinogenesis. 2008 Oct;29(10):1963-6. doi: 10.1093/carcin/bgn172. Epub 2008 Jul 27.
A G to C polymorphism (rs2910164) is located within the sequence of miR-146a precursor, which leads to a change from a G:U pair to a C:U mismatch in its stem region. The predicted miR-146a target genes include BRCA1 and BRCA2, which are key breast and ovarian cancer genes. To examine whether rs2910164 plays any role in breast and/or ovarian cancer, we studied associations between this polymorphism and age of diagnosis in 42 patients with familial breast cancer and 82 patients with familial ovarian cancer. Breast cancer patients who had at least one miR-146a variant allele were diagnosed at an earlier age than with no variant alleles (median age 45 versus 56, P = 0.029) and ovarian cancer patients who had at least one miR-146a variant allele were diagnosed younger than women without any variant allele (median age 45 versus 50, P = 0.014). In further functional analysis, we found that the variant allele displayed increased production of mature miR-146a from the precursor microRNA compared with the common allele. Consistent with the target prediction, in a target in vitro assay, we observed that miR-146a could bind to the 3' untranslated regions (UTRs) of BRCA1 and BRCA2 messenger RNAs (mRNAs) and potentially modulate their mRNA expression. Intriguingly, the binding capacity between the 3' UTR of BRCA1 and miR-146a was statistically significantly stronger in variant C allele than those in common G allele (P = 0.046). Taken together, our data suggest that breast/ovarian cancer patients with variant C allele miR-146a may have high levels of mature miR-146 and that these variants predispose them to an earlier age of onset of familial breast and ovarian cancers.
一个G到C的多态性位点(rs2910164)位于miR-146a前体序列内,这导致其茎区从G:U碱基对变为C:U错配。预测的miR-146a靶基因包括BRCA1和BRCA2,它们是乳腺癌和卵巢癌的关键基因。为了研究rs2910164是否在乳腺癌和/或卵巢癌中发挥作用,我们研究了该多态性与42例家族性乳腺癌患者和82例家族性卵巢癌患者诊断年龄之间的关联。至少有一个miR-146a变异等位基因的乳腺癌患者比没有变异等位基因的患者诊断年龄更早(中位年龄45岁对56岁,P = 0.029),并且至少有一个miR-146a变异等位基因的卵巢癌患者比没有任何变异等位基因的女性诊断年龄更小(中位年龄45岁对50岁,P = 0.014)。在进一步的功能分析中,我们发现与常见等位基因相比,变异等位基因从前体微小RNA产生的成熟miR-146a产量增加。与靶标预测一致,在体外靶标试验中,我们观察到miR-146a可以与BRCA1和BRCA2信使核糖核酸(mRNA)的3'非翻译区(UTR)结合,并可能调节它们的mRNA表达。有趣的是,BRCA1的3'UTR与miR-146a之间 的结合能力在变异C等位基因中比在常见G等位基因中在统计学上显著更强(P = 0.046)。综上所述,我们的数据表明,具有变异C等位基因miR-146a的乳腺癌/卵巢癌患者可能具有高水平的成熟miR-146,并且这些变异使他们易患家族性乳腺癌和卵巢癌的发病年龄更早。